Companies: Highmark Health, HaloMD
HaloMD Lawsuit Update: Highmark Health Alleges 'Sham Letter' and Misleading Data in No Surprises Act Dispute
0% citation coverage
Highmark Health has filed a lawsuit against HaloMD, alleging the No Surprises Act middleman used a 'sham letter' and misleading data to extract inflated payments. This is the fourth such lawsuit from an insurer, highlighting growing tensions over arbitration abuse.
Executive Summary
- Highmark Health sues HaloMD, alleging a 'sham letter' and misleading data to inflate payments under the No Surprises Act.
- This is the fourth insurer lawsuit against HaloMD, following actions by Anthem and Blue Cross Blue Shield of Texas.
- A federal judge dismissed one of the four lawsuits in April 2026, but legal pressure on HaloMD continues to mount.
Show 1 more takeaway
- The case highlights ongoing disputes over arbitration abuse and the role of third-party middlemen in No Surprises Act disputes.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
HaloMD Lawsuit Update: Highmark Health Alleges 'Sham Letter' and Misleading Data in No Surprises Act Dispute
Highmark Health has filed a lawsuit against HaloMD, alleging the No Surprises Act middleman used a 'sham letter' and misleading data to extract inflated payments. This is the fourth such lawsuit from an insurer, highlighting growing tensions over arbitration abuse. In this HaloMD lawsuit update, the Pittsburgh-based insurer's complaint represents the latest legal assault on the third-party arbitration specialist's business practices, following a STAT+ report that detailed the allegations.
Key Takeaways
- Highmark Health sues HaloMD, alleging a 'sham letter' and misleading data to inflate payments under the No Surprises Act.
- This is the fourth insurer lawsuit against HaloMD, following actions by Anthem and Blue Cross Blue Shield of Texas.
- A federal judge dismissed one of the four lawsuits in April 2026, but legal pressure on HaloMD continues to mount.
- The case highlights ongoing disputes over arbitration abuse and the role of third-party middlemen in No Surprises Act disputes.
What is the latest development in the HaloMD litigation?
On June 3, 2026, Highmark Health filed a lawsuit against HaloMD, a company that represents providers in No Surprises Act arbitration disputes. Highmark alleges that HaloMD used a “sham letter” and misleading data to wrongfully extract inflated payments. According to the complaint, HaloMD's tactics represent a “deliberate effort to wrongfully extract inflated payments” from the insurer. This marks the fourth such lawsuit from an insurer, following similar actions by Anthem in March 2026 and Blue Cross Blue Shield of Texas earlier this year.
The Blue Cross Blue Shield of Texas case, filed in federal court, accused HaloMD of double-dipping by filing overlapping disputes for the same services. While a federal judge dismissed one of the four pending lawsuits against HaloMD in April 2026—a case brought by Blue Shield of California—the remaining three, including Highmark's new action, remain active. HaloMD has previously argued that the insurers’ attempts to relitigate No Surprises Act determinations are without merit, with the company noting it was the fourth federal court in six weeks to reject such claims.
How do these legal actions affect pharma teams?
For pharmaceutical and healthcare stakeholders, this lawsuit signals increased scrutiny of third-party arbitration services under the No Surprises Act (PDF). Insurers are aggressively challenging what they see as abuse of the independent dispute resolution (IDR) process. Pharma teams should monitor these cases as they could lead to regulatory changes or tighter rules on IDR submissions. The outcome may affect how providers and insurers negotiate payment disputes, potentially impacting drug pricing and reimbursement strategies. If courts side with insurers, it could curb the influence of middlemen like HaloMD, reshaping the financial incentives in surprise billing disputes. The growing legal pushback creates uncertainty for any third-party service that relies on the IDR process to generate revenue.
Frequently Asked Questions
What is the No Surprises Act arbitration process?
The No Surprises Act, effective January 2022, established an independent dispute resolution (IDR) process to resolve payment disputes between insurers and out-of-network providers for surprise medical bills. When parties cannot agree on a payment amount, they submit offers to an IDR entity, which selects one based on the median in-network rate and other factors. This process is designed to protect patients from balance billing while ensuring fair compensation for providers.
What is HaloMD’s role in IDR disputes?
HaloMD is a third-party arbitration specialist that represents providers in No Surprises Act IDR disputes. The company prepares and manages submissions on behalf of healthcare providers, aiming to secure higher payments from insurers. Its business model relies on the volume of disputes it manages, which has drawn criticism from insurers who allege it exploits the arbitration process for profit.
Why are insurers suing HaloMD?
Insurers, including Highmark Health, Anthem, and Blue Cross Blue Shield of Texas, claim that HaloMD uses unethical tactics—such as submitting “sham letters” and misleading data—to inflate payment amounts awarded through IDR. The lawsuits allege that these practices violate the No Surprises Act and constitute a deliberate effort to extract inflated payments. Highmark’s complaint specifically accuses HaloMD of a “sham letter” intended to mislead the IDR process.
What was the outcome of the dismissed lawsuit against HaloMD?
In April 2026, a federal judge dismissed a lawsuit brought by Blue Shield of California against HaloMD. The court ruled that the insurer’s claims were preempted by the No Surprises Act’s dispute resolution framework. HaloMD described the dismissal as a validation of its operations, noting it was the fourth federal court to reject insurer attempts to relitigate IDR determinations. Despite this win, the company still faces three active lawsuits from other insurers.
Related coverage
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
